Search results for "Positive"

showing 10 items of 1875 documents

B cells participate in thymic negative selection of murine auto-reactive CD4+ T cells.

2010

It is well documented that thymic epithelial cells participate in the process of negative selection in the thymus. In recent years it was reported that also dendritic cells enter the thymus and contribute to this process, thus allowing for the depletion of thymocytes that are specific to peripherally expressed self-antigens. Here we report that also B cells may take part in the elimination of auto-reactive thymocytes. Using a unique mouse model we show that B cells induce negative selection of self-reactive thymocytes in a process that leads to the deletion of these cells whereas regulatory T cells are spared. These findings have direct implication in autoimmunity, as expression of a myelin…

CD4-Positive T-LymphocytesB CellsImmune CellsImmunologyCD1Antigen-Presenting Cellslcsh:MedicineAutoimmunityMice TransgenicThymus GlandBiologyMiceNegative selectionAntigenImmune ToleranceAnimalsIL-2 receptorAntigen-presenting celllcsh:ScienceBiologyClonal AnergyB-LymphocytesMultidisciplinaryCD40Clonal anergyT Cellslcsh:RImmunityCell biologyImmunologyInterleukin 12biology.proteinlcsh:QResearch ArticlePLoS ONE
researchProduct

Tumor-specific T cell activation by recombinant immunoreceptors: CD3 zeta signaling and CD28 costimulation are simultaneously required for efficient …

2001

Abstract Recombinant immunoreceptors with specificity for the carcinoembryonic Ag (CEA) can redirect grafted T cells to a MHC/Ag-independent antitumor response. To analyze receptor-mediated cellular activation in the context of CD28 costimulation, we generated: 1) CEA+ colorectal tumor cells that express simultaneously B7-1 and B7-2, and 2) CEA-specific immunoreceptors that harbor intracellularly the signaling moities either of CD28 (BW431/26-scFv-Fc-CD28), CD3ζ (BW431/26-scFv-Fc-CD3ζ), or FcεRIγ (BW431/26-scFv-Fc-γ). By retroviral gene transfer, we grafted activated T cells from the peripheral blood with these immunoreceptors. T cells that express the FcεRIγ or CD3ζ signaling receptor lyse…

CD4-Positive T-LymphocytesCD3 ComplexT cellCD3T-LymphocytesImmunologyEpitopes T-Lymphocytechemical and pharmacologic phenomenaBiologyCD8-Positive T-LymphocytesMajor histocompatibility complexLymphocyte ActivationTransfectionEpitopeAntigenCD28 AntigensAntigens NeoplasmmedicineTumor Cells CulturedImmunology and AllergyHumansReceptors ImmunologicReceptorReceptors IgGCD28hemic and immune systemsMolecular biologyCoculture TechniquesRecombinant ProteinsCell biologyCarcinoembryonic Antigenmedicine.anatomical_structurebiology.proteinB7-1 AntigenInterleukin-2CD8Signal TransductionJournal of immunology (Baltimore, Md. : 1950)
researchProduct

In vitro generation of CD4+CD25+ regulatory cells from murine naive T cells

2007

CD4+ CD25+ regulatory T cells (Tregs) are crucial for the maintenance of immunological tolerance. Recent data indicate that Tregs not only develop in the thymus during ontogeny but can also differentiate from naive T cells in the periphery. The following protocol describes a method by which Tregs are generated in vitro by stimulation of naive T cells in the presence of transforming growth factor beta (Ti-Tregs). In vitro-induced regulatory T cells express markers of conventional Treg such as CD25 and the genetic program committing transcription factor FoxP3. Functionally the in vitro-generated Ti-Tregs suppress T-cell activation and proliferation while in vivo these cells have been proven t…

CD4-Positive T-LymphocytesCD3 ComplexT-Lymphocytesmedicine.medical_treatmentchemical and pharmacologic phenomenaBiologyBioinformaticsT-Lymphocytes RegulatoryGeneral Biochemistry Genetics and Molecular BiologyMiceInterleukin 21CD28 AntigensmedicineAnimalsCytotoxic T cellIL-2 receptorInterleukin 3Mice Inbred BALB CInterleukin-2 Receptor alpha SubunitFOXP3hemic and immune systemsTransfectionImmunotherapyTransforming growth factor betaCell biologyCD4 Antigensbiology.proteinBiomarkersNature Protocols
researchProduct

Redirection of T cells by delivering a transgenic mouse-derived MDM2 tumor antigen-specific TCR and its humanized derivative is governed by the CD8 c…

1999

Retroviral transfer of T cell antigen receptor (TCR) genes selected by circumventing tolerance to broad tumor- and leukemia-associated antigens in human leukocyte antigen (HLA)-A*0201 (A2.1) transgenic (Tg) mice allows the therapeutic reprogramming of human T lymphocytes. Using a human CD8 x A2.1/Kb mouse derived TCR specific for natural peptide-A2.1 (pA2.1) complexes comprising residues 81-88 of the human homolog of the murine double-minute 2 oncoprotein, MDM2(81-88), we found that the heterodimeric CD8 alpha beta coreceptor, but not normally expressed homodimeric CD8 alpha alpha, is required for tetramer binding and functional redirection of TCR- transduced human T cells. CD8+T cells that…

CD4-Positive T-LymphocytesCD3T cellReceptors Antigen T-Cell alpha-betaImmunologyEpitopes T-LymphocyteMice TransgenicBiologyCD8-Positive T-LymphocytesEpitopeMiceAntigenCell Line TumorHLA-A2 AntigenmedicineCytotoxic T cellAnimalsHumansReverse Transcriptase Polymerase Chain ReactionT-cell receptorProto-Oncogene Proteins c-mdm2Flow CytometryVirologyMolecular biologyTumor antigenmedicine.anatomical_structureSelf Tolerancebiology.proteinCD8Immunologic research
researchProduct

Isolation of CD4+ T cells from murine lungs: a method to analyze ongoing immune responses in the lung.

2007

The regulation of the cellular immune response in lung diseases is not yet fully understood. Isolating different subsets of immune cells directly from the lung is therefore an indispensable method of gaining detailed knowledge on the function of these cells in this organ. This protocol describes a method of isolating and magnetically labeling CD4+ lung T cells, which are then loaded and retained on the column while all other cells run through it (positive selection). The yield of this isolation is approximately 5 x 10(5) to 1.5 x 10(6) CD4+ cells from a murine lung. These cells can be further investigated by several methods such as flow cytometry, western blot analysis, RT-PCR, immunostaini…

CD4-Positive T-LymphocytesCD40biologyStreptamerCell SeparationMolecular biologyGeneral Biochemistry Genetics and Molecular BiologyInterleukin 21Micebiology.proteinInterleukin 12Cytotoxic T cellAnimalsIL-2 receptorAntigen-presenting cellLungInterleukin 3Nature protocols
researchProduct

MHC class II-expressing hepatocytes function as antigen-presenting cells and activate specific CD4 T lymphocyutes.

2003

The ability to activate CD4 T cells is restricted to antigen-presenting cells that express major histocompatibility complex (MHC) class II molecules. Parenchymal cells normally do not express MHC class II molecules; however, in clinical hepatitis, viral or autoimmune, hepatocytes often exhibit aberrant MHC class II expression. It is not known whether MHC class II-expressing hepatocytes can function as antigen-presenting cells, but it has been suggested that aberrant MHC class II expression by parenchymal cells may cause autoimmune disease. Therefore, we generated transgenic mice that specifically overexpress class II transactivator molecules in hepatocytes. Hepatocytes from these mice exhib…

CD4-Positive T-LymphocytesCD74Antigen presentationCD1Antigen-Presenting CellsGene ExpressionMice Inbred StrainsMice TransgenicLymphocyte ActivationHepatitisMiceMHC class ICytotoxic T cellAnimalsMHC class IIHepatologybiologyAntigen processingHistocompatibility Antigens Class IINuclear ProteinsMHC restrictionCell biologyImmunologybiology.proteinHepatocytesTrans-ActivatorsHepatology (Baltimore, Md.)
researchProduct

A Key Regulatory Role of the Transcription Factor NFATc2 in Bronchial Adenocarcinoma via CD8+ T Lymphocytes

2009

AbstractThe Ca2+-regulated calcineurin/nuclear factor of activated T cells (NFAT) cascade controls alternative pathways of T-cell activation and peripheral tolerance. Here, we describe reduction of NFATc2 mRNA expression in the lungs of patients with bronchial adenocarcinoma. In a murine model of bronchoalveolar adenocarcinoma, mice lacking NFATc2 developed more and larger solid tumors than wild-type littermates. The extent of central tumor necrosis was decreased in the tumors in NFATc2(−/−) mice, and this finding was associated with reduced tumor necrosis factor-α and interleukin-2 (IL-2) production by CD8+ T cells. Adoptive transfer of CD8+ T cells of NFATc2(−/−) mice induced transforming…

CD4-Positive T-LymphocytesCancer ResearchAdoptive cell transferTranscription GeneticTransplantation HeterologousMice TransgenicReceptors Nerve Growth FactorAdenocarcinomaCD8-Positive T-LymphocytesBiologyReceptors Tumor Necrosis FactorTransforming Growth Factor beta1Interferon-gammaMiceGlucocorticoid-Induced TNFR-Related ProteinAnimalsHumansIL-2 receptorInterleukin-7 receptorMice Inbred BALB CReceptors Interleukin-7NFATC Transcription FactorsTumor Necrosis Factor-alphaBronchial NeoplasmsInterleukin-2 Receptor alpha SubunitPeripheral toleranceForkhead Transcription FactorsNFATCalcineurinDisease Models AnimalOncologyCancer researchInterleukin-2Tumor necrosis factor alphaCD8Cancer Research
researchProduct

SOCS3 transactivation by PPARγ prevents IL-17-driven cancer growth.

2013

Abstract Activation of the transcription factor PPARγ by the n-3 fatty acid docosahexaenoic acid (DHA) is implicated in controlling proinflammatory cytokine secretion, but the intracellular signaling pathways engaged by PPARγ are incompletely characterized. Here, we identify the adapter-encoding gene SOCS3 as a critical transcriptional target of PPARγ. SOCS3 promoter binding and gene transactivation by PPARγ was associated with a repression in differentiation of proinflammatory T-helper (TH)17 cells. Accordingly, TH17 cells induced in vitro displayed increased SOCS3 expression and diminished capacity to produce interleukin (IL)-17 following activation of PPARγ by DHA. Furthermore, naïve CD4…

CD4-Positive T-LymphocytesCancer ResearchAngiogenesisMammary Neoplasms Experimental/genetics/pathology/prevention & controlSuppressor of Cytokine Signaling Proteinsddc:616.07BioinformaticsTransactivationMice0302 clinical medicineTumor Burden/drug effects/geneticsSOCS3Docosahexaenoic Acids/administration & dosage/pharmacologyPromoter Regions GeneticMice Knockout0303 health sciencesMice Inbred BALB CChemistryReverse Transcriptase Polymerase Chain ReactionInterleukin-17InterleukinCell DifferentiationCell biologyTumor BurdenOncology030220 oncology & carcinogenesisFemaleRNA InterferenceInterleukin 17Th17 Cells/drug effects/metabolismTranscriptional ActivationDocosahexaenoic AcidsBlotting WesternMice NudeCD4-Positive T-Lymphocytes/drug effects/metabolismProinflammatory cytokine03 medical and health sciencesSuppressor of Cytokine Signaling Proteins/genetics/metabolismCell Line TumorAnimalsTranscription factor030304 developmental biologyMammary Neoplasms ExperimentalPromoter Regions Genetic/geneticsDietMice Inbred C57BLPPAR gammaInterleukin-17/metabolismCell cultureSuppressor of Cytokine Signaling 3 ProteinCell Differentiation/drug effectsPPAR gamma/agonists/genetics/metabolismTh17 CellsCancer research
researchProduct

CD39 is highly involved in mediating the suppression activity of tumor-infiltrating CD8+ T regulatory lymphocytes

2013

CD39 is an ectoenzyme, present on different immune cell subsets, which mediates immunosuppressive functions catalyzing ATP degradation. It is not known whether CD39 is expressed and implicated in the activity of CD8+ regulatory T lymphocytes (Treg). In this study, CD39 expression and function was analyzed in both CD8+ and CD4+CD25hi Treg from the peripheral blood of healthy donors as well as from tumor specimens. CD39 was found expressed by both CD8+ (from the majority of healthy donors and tumor patients) and CD4+CD25 hi Treg, and CD39 expression correlated with suppression activity mediated by CD8+ Treg. Importantly, CD39 counteraction remarkably inhibited the suppression activity of CD8+…

CD4-Positive T-LymphocytesCancer ResearchImmunologyAntineoplastic Agentschemical and pharmacologic phenomenaCD8-Positive T-LymphocytesBiologyT-Lymphocytes RegulatoryImmune toleranceAntineoplastic AgentLymphocytes Tumor-InfiltratingImmune systemAntigenAntigens CDImmune TolerancemedicineHumansIndoleamine-Pyrrole 23-DioxygenaseImmunology and AllergyCell ProliferationCD39Tumor microenvironmentCell growthApyraseInterleukin-2 Receptor alpha SubunitCD8-Positive T-LymphocyteTumor immune escapePhenotypePhenotypeCD39 CD8+ Treg Tumor immune escape ToleranceMicroscopy FluorescenceOncologyMechanism of actionCD4-Positive T-LymphocyteImmunologyCD8+ Tregmedicine.symptomToleranceCD8HumanCancer Immunology, Immunotherapy
researchProduct

MHCII-independent CD4+ T cells protect injured CNS neurons via IL-4

2015

A body of experimental evidence suggests that T cells mediate neuroprotection following CNS injury; however, the antigen specificity of these T cells and how they mediate neuroprotection are unknown. Here, we have provided evidence that T cell-mediated neuroprotection after CNS injury can occur independently of major histocompatibility class II (MHCII) signaling to T cell receptors (TCRs). Using two murine models of CNS injury, we determined that damage-associated molecular mediators that originate from injured CNS tissue induce a population of neuroprotective, IL-4-producing T cells in an antigen-independent fashion. Compared with wild-type mice, IL-4-deficient animals had decreased functi…

CD4-Positive T-LymphocytesCancer ResearchMAP Kinase Signaling SystemPopulationReceptors Antigen T-CellInflammationBiologyNeuroprotectionMiceAntigenClinical investigationAnimalsMedicineExtracellular Signal-Regulated MAP KinaseseducationReceptorInterleukin 4Mice Knockouteducation.field_of_studybusiness.industryT-cell receptorHistocompatibility Antigens Class IINeurodegenerative DiseasesGeneral MedicineAxonsCell biologyBrain InjuriesMyeloid Differentiation Factor 88Immunologybiology.proteinInterleukin-4medicine.symptomFunction and Dysfunction of the Nervous SystemCorrigendumbusinessProto-Oncogene Proteins c-aktResearch ArticleNeurotrophinJournal of Clinical Investigation
researchProduct